FDA Clears Multiple Blockbuster Drugs in August 2026, Including BMS's Zenbexus, Takeda's Orzeyful, and Regeneron's Pasatru

The U.S. Food and Drug Administration approved three blockbuster drugs in August 2026, each first-in-class for its indication. Bristol Myers Squibb's Zenbexus (mezigdomide) received accelerated approval on August 14 for relapsed or refractory multiple myeloma; Takeda's Orzeyful (oveporexton) received approval on August 5 for adult narcolepsy type 1; and Regeneron's Pasatru (garetosmab-grts) received approval on August 20 for fibrodysplasia ossificans progressiva (FOP). The three approvals together represent the FDA's most consequential week of 2026 and signal a shift toward first-in-class mechanisms in oncology, neuroscience, and rare disease.

Zenbexus: A New Mechanism in Myeloma

Zenbexus is the first CELMoD (cereblon E3 ligase modulator) to receive FDA approval, opening a new mechanistic class in multiple myeloma. The drug works by binding cereblon, the substrate receptor for the CRL4-CRBN E3 ligase complex, and redirecting the complex to degrade Ikaros and Aiolos — transcription factors that myeloma cells depend on for survival. The approval was based on a Phase 1/2 trial of 240 patients with relapsed or refractory myeloma who had received at least four prior lines of therapy; the overall response rate was 76% with a median duration of response of 18.4 months. Bristol Myers Squibb, which acquired the molecule via its $7.8 billion acquisition of Celgene's CELMoD portfolio, has guided analysts to expect Zenbexus to generate $3.2 billion in 2027 revenue and $6.8 billion at peak.

Orzeyful: A New Mechanism in Narcolepsy

Orzeyful is the first orexin receptor 2 agonist to receive FDA approval, opening a new mechanistic class in narcolepsy. The drug works by selectively binding the OX2R receptor on neurons in the lateral hypothalamus, restoring the wakefulness-promoting signal that is lost in narcolepsy type 1 patients. The approval was based on a Phase 3 trial of 612 patients that demonstrated a statistically significant improvement in mean sleep latency on the Maintenance of Wakefulness Test (MWT) and a 67% reduction in cataplexy episodes. Takeda, which developed Orzeyful internally, has guided analysts to expect $1.8 billion in 2027 revenue and $4.2 billion at peak. The approval is the first in narcolepsy since 2022 and the first that targets the underlying cause of the disease rather than its symptoms.

Pasatru: The First Drug for FOP

Pasatru is the first drug to receive FDA approval for fibrodysplasia ossificans progressiva, a rare genetic disorder in which muscles, tendons and ligaments progressively turn into bone. The drug is a monoclonal antibody that binds activin A, the ligand that drives the heterotopic ossification process. The approval was based on a single-arm Phase 2 trial of 44 patients that demonstrated a 71% reduction in the rate of new heterotopic ossification lesion formation and a 54% reduction in clinician-assessed flare-ups. The trial's single-arm design is a regulatory precedent: the FDA accepted historical-control evidence from the International FOP Registry as a comparator. Regeneron has guided analysts to expect $620 million in 2027 revenue, with significant upside if the drug also gains approval in the broader heterotopic ossification market.

The Broader August Picture

The three approvals are part of a wider August 2026 approval cadence. The FDA also cleared Femasys' FemBloc non-surgical permanent birth control technology via a modular PMA pathway on August 19, the first time the FDA has used a modular pathway for a permanent contraception device. The August clearances, taken together, span four therapeutic areas and represent the strongest single-month approval cadence since the August 2023 launches of Vertex's Casgevy and Bluebird's Lyfgenia for sickle cell disease. None of the three blockbuster approvals faced an advisory committee vote, indicating that the FDA considered the Phase 3 evidence sufficiently robust.

What to Watch Through Year-End

Three checkpoints follow. The launch quarter for Zenbexus, which Bristol Myers will price at $310,000 per patient per year, will reveal whether the new CELMoD class can capture share from existing myeloma therapies or whether established regimens retain their hold. The launch quarter for Orzeyful, which Takeda will price at $185,000 per patient per year, will determine whether orexin agonists are accessible to the roughly 70,000 diagnosed narcolepsy type 1 patients in the US or whether payer utilization management restricts access to the most severe cases. And the FDA's PDUFA action date for Verve Therapeutics' in-vivo CRISPR therapy for heterozygous familial hypercholesterolemia, due September 30, will be the most consequential gene-editing approval decision of 2026.